Oncogenic Signal and Tumor Microenvironment in Hepatocellular Carcinoma

Area of Science:

• Oncology
• Immunology
• Cancer Biology

Background:

• Tumor development involves immunosuppressive molecules creating a hostile microenvironment.
• Cytokines, chemokines, growth factors, and metabolites in tumors can impede immune checkpoint inhibitors.
• Monotherapy with anti-PD-1/PD-L1 antibodies may be insufficient for robust antitumor responses.

Purpose of the Study:

• To review the immunosuppressive microenvironment in hepatocellular carcinoma.
• To explore how oncogenic signaling contributes to this immunosuppression.
• To discuss overcoming immunosuppression with tyrosine kinase inhibitors.

Main Methods:

• Literature review focusing on hepatocellular carcinoma.
• Analysis of molecular mechanisms driving immunosuppression.
• Evaluation of combination therapies involving tyrosine kinase inhibitors and immune checkpoint inhibitors.

Main Results:

• Immunosuppressive molecules are key to tumor progression and resistance to immunotherapy.
• Genetic/epigenetic alterations and environmental factors activate immunosuppressive pathways.
• Tyrosine kinase inhibitors show potential in combination with anti-PD-1/PD-L1 therapy.

Conclusions:

• Targeting immunosuppressive molecules is crucial for enhancing anti-PD-1/PD-L1 efficacy.
• Combination strategies are needed to overcome hepatocellular carcinoma's immunosuppressive tumor microenvironment.
• Tyrosine kinase inhibitors represent a promising approach to reverse immunosuppression and boost antitumor immunity.